Penbutolol in black hypertensive patients.
A single-blind placebo-controlled study was conducted on black hypertensive patients with a once-daily dose of penbutolol (Betapressin; Hoechst); a non-selective beta-blocker. Of 29 patients who participated in a 4-week run-in period, 18 were entered into a 20-week trial of the active medication. Fourteen patients were adequately controlled, 2 did not respond satisfactorily and 2 dropped out of the study. On cessation of therapy all patients became hypertensive again. No significant changes in mean heart rates were observed during active medication as opposed to placebo. Penbutolol can therefore be used as a sole antihypertensive agent in blacks.